Search PubMed⌕ Search

Biomedical subjects

R Tanaka

Publications and source records attributed to R Tanaka.

At least 775 records · Page 43Linked to original sources
PubMed1983

Treatment of moyamoya disease by temporal muscle graft 'encephalo-myo-synangiosis'.

10 young patients from 7 to 16 years of age with moyamoya disease were treated by temporal muscle graft (encephalo-myo-synangiosis: EMS) for the purpose of increasing extracranial and intracranial collateral circulation. Ischemic cerebrovascular symptoms and signs were encountered in all of them without intracranial hemorrhage. The patients were observed for 6-26 months after the first operation. Transient ischemic attacks disappeared in 4 out of 7 patients, and improved in frequency and duration in the remaining 3. Paresis of the limbs disappeared in 1 patient and improved in 2. In 2 patients, facial palsy disappeared and dysarthria improved as well. Ataxia disappeared in 2 patients, and involuntary movement of the extremities disappeared in 2. There were no ineffective cases clinically. In postoperative carotid angiography, the middle cerebral arteries were visualized clearly to the peripheral portion mainly via the thickened deep temporal arteries, and the abnormal vascular networks in the region of the basal ganglia reduced in size in most of patients. Improvements in intelligence quotient, electroencephalogram and cerebral blood flow were also obtained in several patients, respectively. EMS seemed to be an effective surgical treatment in young patients with moyamoya disease who suffered from cerebral ischemic symptoms.

Adolescent↗
PubMed1983

Computed tomographic arteriography in the diagnosis of hepatocellular carcinoma.

Computed tomographic arteriography (CTA) was performed in 30 patients with hepatocellular carcinoma (HCC). Detection of HCC by CTA was compared with that of conventional celiac or hepatic arteriography. CT scanning was performed immediately, 30 seconds and 1 min after an injection of 5 to 10 ml of contrast medium into the common or proper hepatic artery. Repeated infusions allowed whole liver sections to be visualized. HCC was localized in 28 of the 30 patients by conventional arteriography, with CTA detecting the masses in 27 of the 28 patients. CTA imaging presented the tumor mass in 1 of the 2 patients missed by arteriography. Conventional arteriography delineated the boundaries of HCC in 15 (50%) of the 30 patients. CTA clearly delineated the masses in 26 (87%) of the 30 patients including 11 patients in which the tumor borders were obscure by conventional arteriography. HCC lesions smaller than 1 cm in diameter were detected only by CTA in 6 (20%) of the patients. It was concluded that CTA is both useful and necessary in the demarcation of small HCC masses.

Angiography↗
PubMed1983

Paraquat-induced enhancement of vascular permeability.

Paraquat, intradermally injected in the dorsal skin of rats, demonstrated three phasic actions; enhancement of vascular permeability within 30 min (Phase I) and at 6-24 hr after the injection (Phase II) by dye leakage method and bleeding in skin at 2-7 days after the injection (Phase III). Phase I was induced in the presence of paraquat in the skin. However, phases II and III occurred in the absence of paraquat. Morphological study indicated inflammatory observations such as infiltration of mononuclear cells and swelling of venular endothelial cells throughout these three phases. And the most severe morphological changes occurred in phase II. Aspirin, indomethacin, tripelennamine and dexamethasone decreased dye leakage but superoxide dismutase increased it in phase I. These drugs including superoxide dismutase decreased dye leakage in phase II. Bleeding in phase III was decreased by the administration of aspirin and indomethacin. Because of higher effective dose of indomethacin used in this experiment as compared with a clinical dose, aspirin seemed among drugs examined in our experimental models to be the most potent drug that depressed the progression of paraquat-induced enhancement of permeability.

Animals↗
PubMed1983

[Clinical evaluation of cefroxadine in bacterial infections of the eye].

Cefroxadine (CXD) capsules and dry syrup, an oral cephem antibiotic, were administered into 120 cases with ocular infections and the following results were obtained: The daily dose of CXD capsule was ranged from 500 to 1,500 mg and that of CXD dry syrup from 17.9 to 85.7 mg/kg, and the duration of CXD administration was from 2 days to 14 days. Clinical response rates classified by diagnosis The clinical response rates were 77.8% (14/18) in blepharitis, 86.7% (26/30) in hordeolum, 62.5% (5/8) in meibomianitis, 74.6% (44/59) in conjunctivitis, 100% (2/2) in corneal infiltration, 100% (1/1) in cellulitis of the lid, in dacryocystitis and in corneal ulcer, respectively. Clinical response classified by isolated organisms The response rates on S. aureus were 80.0% (20/25), on S. epidermidis 75.8% (47/62) and on S. pneumoniae 66.7% (2/3), respectively. The overall clinical response rate on Gram-positive bacteria was 78.3% (94/120). The response rates on H. influenzae, Acinetobacter spp., P. mirabilis, E. coli and Moraxella spp. were ranged from 42.9 to 100%. The sensitivity distributions of clinically isolated S. aureus and S. epidermidis to CXD were ranged from 1.56 to greater than 100 micrograms/ml and from 0.39 to 12.5 micrograms/ml, respectively. The former showed a peak at 3.13 micrograms/ml and the latter in 1.56 micrograms/ml. Side effects in 3 cases (2.3%) out of 129 were observed. That is; glossitis, thirst feeling and palpitation in each case, respectively.

Administration, Oral↗